Noor Muhammad, Muhammad Sohail Afzal, Ute Hamann, Muhammad Usman Rashid
{"title":"致病性 RAD51D 基因变异对巴基斯坦早发和家族性乳腺癌/卵巢癌患者的影响微乎其微。","authors":"Noor Muhammad, Muhammad Sohail Afzal, Ute Hamann, Muhammad Usman Rashid","doi":"10.37029/jcas.v10i2.617","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>RAD51D</i> has been reported as a breast cancer (BC) and ovarian cancer (OC) predisposition gene, particularly among Caucasian populations. We studied the prevalence of <i>RAD51D</i> variants in Pakistani BC/OC patients.</p><p><strong>Materials and methods: </strong>In total, 371 young or familial BC/OC patients were thoroughly analyzed for <i>RAD51D</i> sequence variants using denaturing high-performance liquid chromatography pursued by DNA sequencing of differentially eluted amplicons. We also assessed the pathogenic effects of novel variants using in-silico algorithms. All detected <i>RAD51D</i> variants were investigated in 400 unaffected controls.</p><p><strong>Results: </strong>No pathogenic <i>RAD51D</i> variant was detected. However, we identified nine unique heterozygous variants. Of these, two missense variants (p.Pro10Leu and p.Ile311Asn) and one intronic variant (c.481-26_23delGTTC) were classified as in silico-predicted variants of uncertain significance, with a frequency of 0.8% (3/371). The p.Pro10Leu variant was detected in a 28-year-old female BC patient of Punjabi ethnic background, whose mother and maternal cousin had BCs at ages 53 and 40, respectively. This variant was also detected in 1/400 (0.25%) healthy controls, where the control subject's daughter had acute lymphoblastic leukemia. The p.Ile311Asn variant was identified in a female BC patient at age 29 of Punjabi ethnicity and in 1/400 (0.25%) healthy controls, where the control subject's daughter had Hodgkin's disease at age 14. A novel intronic variant, c.481-26_-23delGTTC, was found in a 30-year-old Punjabi female BC patient but not in 400 healthy controls.</p><p><strong>Conclusion: </strong>No pathogenic <i>RAD51D</i> variant was identified in the current study. Our study data suggested a negligible association of <i>RAD51D</i> variants with BC/OC risk in Pakistani women.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"10 2","pages":"617"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326667/pdf/","citationCount":"0","resultStr":"{\"title\":\"Marginal Contribution of Pathogenic <i>RAD51D</i> Germline Variants to Pakistani Early-Onset and Familial Breast/Ovarian Cancer Patients.\",\"authors\":\"Noor Muhammad, Muhammad Sohail Afzal, Ute Hamann, Muhammad Usman Rashid\",\"doi\":\"10.37029/jcas.v10i2.617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong><i>RAD51D</i> has been reported as a breast cancer (BC) and ovarian cancer (OC) predisposition gene, particularly among Caucasian populations. We studied the prevalence of <i>RAD51D</i> variants in Pakistani BC/OC patients.</p><p><strong>Materials and methods: </strong>In total, 371 young or familial BC/OC patients were thoroughly analyzed for <i>RAD51D</i> sequence variants using denaturing high-performance liquid chromatography pursued by DNA sequencing of differentially eluted amplicons. We also assessed the pathogenic effects of novel variants using in-silico algorithms. All detected <i>RAD51D</i> variants were investigated in 400 unaffected controls.</p><p><strong>Results: </strong>No pathogenic <i>RAD51D</i> variant was detected. However, we identified nine unique heterozygous variants. Of these, two missense variants (p.Pro10Leu and p.Ile311Asn) and one intronic variant (c.481-26_23delGTTC) were classified as in silico-predicted variants of uncertain significance, with a frequency of 0.8% (3/371). The p.Pro10Leu variant was detected in a 28-year-old female BC patient of Punjabi ethnic background, whose mother and maternal cousin had BCs at ages 53 and 40, respectively. This variant was also detected in 1/400 (0.25%) healthy controls, where the control subject's daughter had acute lymphoblastic leukemia. The p.Ile311Asn variant was identified in a female BC patient at age 29 of Punjabi ethnicity and in 1/400 (0.25%) healthy controls, where the control subject's daughter had Hodgkin's disease at age 14. A novel intronic variant, c.481-26_-23delGTTC, was found in a 30-year-old Punjabi female BC patient but not in 400 healthy controls.</p><p><strong>Conclusion: </strong>No pathogenic <i>RAD51D</i> variant was identified in the current study. Our study data suggested a negligible association of <i>RAD51D</i> variants with BC/OC risk in Pakistani women.</p>\",\"PeriodicalId\":73631,\"journal\":{\"name\":\"Journal of cancer & allied specialties\",\"volume\":\"10 2\",\"pages\":\"617\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326667/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer & allied specialties\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37029/jcas.v10i2.617\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer & allied specialties","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37029/jcas.v10i2.617","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Marginal Contribution of Pathogenic RAD51D Germline Variants to Pakistani Early-Onset and Familial Breast/Ovarian Cancer Patients.
Introduction: RAD51D has been reported as a breast cancer (BC) and ovarian cancer (OC) predisposition gene, particularly among Caucasian populations. We studied the prevalence of RAD51D variants in Pakistani BC/OC patients.
Materials and methods: In total, 371 young or familial BC/OC patients were thoroughly analyzed for RAD51D sequence variants using denaturing high-performance liquid chromatography pursued by DNA sequencing of differentially eluted amplicons. We also assessed the pathogenic effects of novel variants using in-silico algorithms. All detected RAD51D variants were investigated in 400 unaffected controls.
Results: No pathogenic RAD51D variant was detected. However, we identified nine unique heterozygous variants. Of these, two missense variants (p.Pro10Leu and p.Ile311Asn) and one intronic variant (c.481-26_23delGTTC) were classified as in silico-predicted variants of uncertain significance, with a frequency of 0.8% (3/371). The p.Pro10Leu variant was detected in a 28-year-old female BC patient of Punjabi ethnic background, whose mother and maternal cousin had BCs at ages 53 and 40, respectively. This variant was also detected in 1/400 (0.25%) healthy controls, where the control subject's daughter had acute lymphoblastic leukemia. The p.Ile311Asn variant was identified in a female BC patient at age 29 of Punjabi ethnicity and in 1/400 (0.25%) healthy controls, where the control subject's daughter had Hodgkin's disease at age 14. A novel intronic variant, c.481-26_-23delGTTC, was found in a 30-year-old Punjabi female BC patient but not in 400 healthy controls.
Conclusion: No pathogenic RAD51D variant was identified in the current study. Our study data suggested a negligible association of RAD51D variants with BC/OC risk in Pakistani women.